United States MAXIGESIC IV (Paracetamol + Ibuprofen) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com
14 Dec 2023
Fast Track
DUBLIN--(BUSINESS WIRE)--The "United States MAXIGESIC IV Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
'United States MAXIGESIC IV Drug Insight and Market Forecast - 2032'
This report provides comprehensive insights about MAXIGESIC IV for acute pain in the United States.
A detailed picture of the MAXIGESIC IV for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the MAXIGESIC IV for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
Further, it also consists of future market assessments inclusive of the MAXIGESIC IV market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain.
Drug Summary
MAXIGESIC IV (paracetamol + ibuprofen), a novel, patented, dual mode-of-action non-opioid pain treatment, is a unique combination of paracetamol (known as acetaminophen in the US) 1,000 mg + ibuprofen 300 mg solution for infusion for use postoperatively in hospitals for patients for whom the use of oral analgesics is limited. This specific combination is designed to allow the maximum daily dose of paracetamol and ibuprofen and to allow for the effect of paracetamol on phenylephrine when combined, the level of phenylephrine crossing into the bloodstream effectively doubles.
MAXIGESIC reduces fever and temporarily relieves pain associated with headaches, migraines, tension headaches, sinus pain, toothache, dental procedures, backache, sore throat, arthritis, tennis elbow, period pain, muscular pain, rheumatic pain, aches and pains associated with colds and flu. The drug is a unique patented combination of paracetamol and ibuprofen, proven to provide fast and effective relief from a wide range of pain symptoms.
MAXIGESIC IV Analytical Perspective
In-depth MAXIGESIC IV Market Assessment
This report provides a detailed market assessment of MAXIGESIC IV for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
MAXIGESIC IV Clinical Assessment
The report provides the clinical trials information of MAXIGESIC IV for acute pain covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MAXIGESIC IV dominance.
Other emerging products for acute pain are expected to give tough market competition to MAXIGESIC IV and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MAXIGESIC IV in acute pain.
Our in-depth analysis of the forecasted sales data of MAXIGESIC IV from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MAXIGESIC IV in acute pain.
Key Questions Answered
What is the product type, route of administration and mechanism of action of MAXIGESIC IV?
What is the clinical trial status of the study related to MAXIGESIC IV in acute pain and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MAXIGESIC IV development?
What are the key designations that have been granted to MAXIGESIC IV for acute pain?
What is the forecasted market scenario of MAXIGESIC IV for acute pain?
What are the forecasted sales of MAXIGESIC IV in the United States?
What are the other emerging products available and how are these giving competition to MAXIGESIC IV for acute pain?
Which are the late-stage emerging therapies under development for the treatment of acute pain?
Key Topics Covered:
1. Report Introduction
2. MAXIGESIC IV Overview in Acute pain
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Regulatory Milestone
2.4. Other Developmental Activities
2.5. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. MAXIGESIC IV Market Assessment
5.1. Market Outlook of MAXIGESIC IV in Acute pain
5.2. The United States Analysis
5.2.1. Market Size of MAXIGESIC IV in the United States for Acute pain
6. SWOT Analysis
7. Analysts' Views
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yk65yr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.